Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. Biomarkers for non-invasively monitoring NAFLD activity and progression are urgently needed. Various studies demonstrated that serological detection of caspase-cleaved cytokeratin (CK)-18 fragments by the M30-ELISA can distinguish between NASH and NAFL patients or healthy individuals, but not between NAFL and healthy persons. There is increasing evidence that NAFL can rapidly progress to NASH. Thus, biomarkers that already allow the identification of NAFL patients that are at risk for disease progression are required. In this study we have evaluated an improved M30-ELISA in patients with NAFLD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
